Aspirin for Cardioprotection and Strategies to Improve Patient Adherence

References

• . Go AS, Mozaffarian D, Roger VL, ; American Heart Association Statistics Committee and Stroke Statistics. Heart disease and stroke statistics—2013 update: a report from the American Heart Association [published corrections appear in Circulation. 2013;127(23):e841]. Circulation. 2013;127(1):e6–e245
   PubMed Web of Science ®Google Scholar
• . Laslett LJ, Alagona P Jr, Clark BA 3rd, . The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60( 25 Suppl):S1–S49
   PubMed Web of Science ®Google Scholar
• . Eckel RH, Jakicic JM, Ard JD, . 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. Circulation. 2013
   Google Scholar
• . Smith SC Jr, Benjamin EJ, Bonow RO, ; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473
   PubMed Web of Science ®Google Scholar
• . Baigent C, Blackwell L, Collins R, . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. May 30 2009;373(9678):1849–1860
   PubMed Web of Science ®Google Scholar
• . US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404
   PubMedGoogle Scholar
• . Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125–141
   PubMedGoogle Scholar
• . Kolber MR, Korownyk C. An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds [published online ahead of print November 11, 2013]. Expert Opin Pharmacother. 2013
   Google Scholar
• . Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006;151(1):185–191
   PubMed Web of Science ®Google Scholar
• . Biondi-Zoccai GG, Lotrionte M, Agostoni P, . A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–2674
   PubMed Web of Science ®Google Scholar
• . Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497
   PubMed Web of Science ®Google Scholar
• . Riegel B, Moser DK, Anker SD, ; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Nutrition, Physical Activity, and Metaboloism; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120(12):1141–1163
   PubMed Web of Science ®Google Scholar
• . Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–1090; discussion 1073
   PubMed Web of Science ®Google Scholar
• . Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438–444
   PubMedGoogle Scholar
• . Eagle KA, Kline-Rogers E, Goodman SG, . Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73–81
   PubMedGoogle Scholar
• . Ho PM, Spertus JA, Masoudi FA, . Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–1847
   PubMedGoogle Scholar
• . Newby LK, LaPointe NM, Chen AY, . Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–212
   PubMed Web of Science ®Google Scholar
• . Kumbhani DJ, Steg PG, Cannon CP, ; REduction of Atherothrombosis for Continued HealthRegistry Investigators. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126(8):693–700
   PubMedGoogle Scholar
• . Bi Y, Gao R, Patel A, ; CPACS Investigators. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009;157(3):509–516
   PubMedGoogle Scholar
• . Kronish IM, Rieckmann N, Burg MM, Alcantara C, Davidson KW. The Psychosocial Context Impacts Medication Adherence After Acute Coronary Syndrome [published online ahead of print October 26, 2013]. Ann Behav Med. 2013
   Google Scholar
• . Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient. 2011;4(2):103–113
   PubMedGoogle Scholar
• . Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887
   PubMed Web of Science ®Google Scholar
• . Lehmann A, Aslani P, Ahmed R, . Assessing medication adherence: options to consider [published online ahead of print October 29, 2013]. Int J Clin Pharm. 2013
   Google Scholar
• . Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310
   PubMed Web of Science ®Google Scholar
• . Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection [published online ahead of print October 16, 2013]. Int J Clin Pharm. 2013
   Google Scholar
• . Casebeer L, Huber C, Bennett N, . Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48. doi: 10.1186/1471-2296-10-48
   PubMed Web of Science ®Google Scholar
• . Arora S, Peters AL, Burner E, Lam CN, Menchine M. Trial to Examine Text Message-Based mHealth in Emergency Department Patients With Diabetes (TExT-MED): A Randomized Controlled Trial. Ann Emerg Med. 2013;pii: S0196-0644(13)0148-8
   Google Scholar
• . George MG, Tong X, Sonnenfeld N, Hong Y; Centers for Disease Control and Prevention (CDC). Recommended use of aspirin and other antiplatelet medications among adults—National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2012;61( Suppl):11–18
   Google Scholar
• . Arnold SV, Spertus JA, Masoudi FA, . Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791–1801
   PubMedGoogle Scholar
• . Mehta RH, Montoye CK, Gallogly M, ; GAP Steering Committee of the American Colege of Cardiology. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287(10):1269–1276
   PubMed Web of Science ®Google Scholar
• . LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203–209
   PubMedGoogle Scholar
• . Eagle KA, Montoye CK, Riba AL, ; American College of Cardiology's Guidelines Applied in Practice (GAP) {rojects in Michigan; American College of Cardiology Foundation (Bethesda, Maryland) Guidelines Applied in Practice Steering Committee. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol. 2005;46(7):1242–1248
   PubMedGoogle Scholar
• . Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther. 2013;38(2):97–100
   PubMedGoogle Scholar
• . McNamara KP, O'Reilly SL, Dunbar JA, . A pilot study evaluating multiple risk factor interventions by community pharmacists to prevent cardiovascular disease: the PAART CVD pilot project. Ann Pharmacother. 2012;46(2):183–191
   PubMed Web of Science ®Google Scholar
• . Albert NM, Fonarow GC, Yancy CW, . Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). Am J Cardiol. 2010;105(12):1773–1779
   PubMedGoogle Scholar
• . Thom S, Poulter N, Field J, ; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–929
   PubMed Web of Science ®Google Scholar
• . Orloff DG. Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach. Am J Cardiol. 2005;96(9 A):28K–33K; discussion 34K–35K
   PubMedGoogle Scholar
• . Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14(1):88–90
   PubMed Web of Science ®Google Scholar
• . Rieckmann N, Kronish IM, Haas D, . Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006;152(5):922–927
   PubMedGoogle Scholar
• . Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med. 1994;154(23):2649–2657
   PubMedGoogle Scholar
• . Toth L, Muszbek L, Komaromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model. 2013;40:99–109
   PubMedGoogle Scholar
• . Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117(1):17–25
   PubMed Web of Science ®Google Scholar
• . Park K, Bavry AA. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events [published corrections appear in Cleve Clin J Med. 2013;80(7)435]. Cleve Clin J Med. 2013;80(5):318–326
   PubMedGoogle Scholar
• . CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339
   PubMed Web of Science ®Google Scholar
• . Laheij RJ, Jansen JB, Verbeek AL, Verheugt FW. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther. 2001;15(7):1055–1059
   PubMedGoogle Scholar
• . Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–173
   PubMed Web of Science ®Google Scholar
• . Cea Soriano L, Rodriguez LA. Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol. 2010;1:126. doi: 10.3389/fphar.2010.0012
   PubMed Web of Science ®Google Scholar
• . Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16(4):779–786
   PubMed Web of Science ®Google Scholar
• . Ng W, Wong WM, Chen WH, . Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol. 2006;12(18):2923–2927
   PubMedGoogle Scholar
• . Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945–1953
   PubMedGoogle Scholar
• . Lanas A, Bajador E, Serrano P, . Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343(12):834–839
   PubMed Web of Science ®Google Scholar
• . de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1
   PubMedGoogle Scholar
• . Lanas A, Garcia-Rodriguez LA, Arroyo MT, ; Asociacion Espanola de Gastroenterologia. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–1738
   PubMed Web of Science ®Google Scholar
• . Weil J, Colin-Jones D, Langman M, . Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827–830
   PubMedGoogle Scholar
• . Udd M, Miettinen P, Palmu A, . Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol. 2007;42(12):1395–1403
   PubMed Web of Science ®Google Scholar
• . Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738
   PubMed Web of Science ®Google Scholar
• . Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26(2):125–140
   PubMed Web of Science ®Google Scholar
• . Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001;32(8):1884–1889
   PubMedGoogle Scholar
• . De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; Dutch TIA trial and SPIRIT study groups. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252(11):1316–1321
   PubMedGoogle Scholar
• . Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke. 1994;25(12):2337–2342
   PubMedGoogle Scholar
• . Wang Y, Wu D, Ma R, Wang C, Zhao W. A survey on adherence to secondary ischemic stroke prevention. Neurol Res. 2006;28(1):16–20
   PubMed Web of Science ®Google Scholar
• . Newby LK, Bhapkar MV, White HD, ; SYMPHONY and 2nd SYMPHONY investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis. 2003;16(3):119–128
   PubMedGoogle Scholar
• . Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217–1220
   PubMedGoogle Scholar
• . Pratt S, Thompson VJ, Elkin EP, Næsdal J, Sorstadius E. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10(5):281–288
   PubMed Web of Science ®Google Scholar
• . Bower AB, Grau SL, Taylor VA. Over-the-counter vs. prescription medications: are consumer perceptions of the consequences of drug instruction non-compliance different? International Journal of Consumer Studies. 2013;37(2)228–233
   Google Scholar
• . Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24(1):35–39
   PubMed Web of Science ®Google Scholar
• . Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):e7–e327
   Google Scholar
• . Quilici J, Fugon L, Beguin S, . Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. Int J Cardiol. 2013;168(1):568–569
   PubMedGoogle Scholar
• . Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348(9039):1413–1416
   PubMed Web of Science ®Google Scholar
• . Yeomans N, Lanas A, Labenz J, . Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465–2473
   PubMed Web of Science ®Google Scholar
• . Sylvester KW, Cheng JW, Mehra MR. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag. 2013;9:245–254
   PubMedGoogle Scholar
• . Martin Merino E, Johansson S, Nagy P, Garcia Rodriguez LA. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care. Am J Cardiol. 2013;112(8):1075–1082
   PubMedGoogle Scholar
• . Hedberg J, Sundstrom J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding—a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med. 2013;274(4):371–380
   PubMed Web of Science ®Google Scholar
• . Mosca L, Benjamin EJ, Berra K, ; American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–1423
   PubMed Web of Science ®Google Scholar
• . Vandvik PO, Lincoff AM, Gore JM, ; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 Suppl):e637S–e6368S
   PubMed Web of Science ®Google Scholar
• . Goldstein LB, Bushnell CD, Adams RJ, ; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [corrections published in Stroke. 2011;42(2):e26]. Stroke. 2011;42(2):517–584
   PubMed Web of Science ®Google Scholar
• . O'Gara PT, Kushner FG, Ascheim DD, ; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425
   PubMed Web of Science ®Google Scholar
• . , 2012 Writing Committee MembersJneid H, Anderson JL, Wright RS, ; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875–910
   PubMedGoogle Scholar
• . Furie KL, Kasner SE, Adams RJ, ; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Clinical Cardiologu; Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227–276
   PubMed Web of Science ®Google Scholar
• . You JJ, Singer DE, Howard PA, ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 Suppl):e531S–e575S
   PubMed Web of Science ®Google Scholar
• . Rooke TW, Hirsch AT, Misra S, ; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Intervenitonal Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guidelines): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020–2045
   PubMed Web of Science ®Google Scholar
• . Brott TG, Halperin JL, Abbara S, ; Amican College of Cardiology; American Stroke Association; American Association of Neurological Surgeons; American College of Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011;124(4):e54–e130
   PubMedGoogle Scholar
• . Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 Suppl):e576S–e600S
   PubMed Web of Science ®Google Scholar
• . Newburger JW, Takahashi M, Gerber MA, ; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–2771
   PubMed Web of Science ®Google Scholar
• . Sud A, Kline-Rogers EM, Eagle KA, . Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005;39(11):1792–1797
   PubMedGoogle Scholar
• . Wald DS, Morton G, Walker K, Iosson N, Curzen NP. Long-term continuation on cardiovascular drug treatment in patients with coronary heart disease. Ann Pharmacother. 2007;41(10):1644–1647
   PubMedGoogle Scholar
• . Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly). J Am Geriatr Soc. 1994;42(6):643–647
   PubMedGoogle Scholar
• . Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17(7):1041–1045
   PubMedGoogle Scholar
• . Frishman WH. Enhancing medical adherence [published corrections appear in Am J Med. 2013;126(6):e25]. Am J Med. 2012;125(9):841–842
   PubMedGoogle Scholar